Noteworthy ETF Inflows: DFAC, CVX, WFC, MRK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Should l Buy MRK?
Source: NASDAQ.COM
DFAC Stock Performance: DFAC's stock has a 52-week range with a low of $28.39 and a high of $36.66, currently trading at $34.37, which is useful for technical analysis when compared to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve buying and selling units that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 119.310
Low
95.00
Averages
119.53
High
139.00
Current: 119.310
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of VONE Stock Performance
- Price Range Analysis: VONE's stock has a 52-week low of $218.75 and a high of $316.38, with the last trade at $314.58, indicating that the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and optimal buying or selling opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
FDA Approves Merck's Keytruda for Ovarian Cancer Treatment
- FDA Approval for New Indication: The FDA approved Merck's Keytruda and Keytruda Qlex for previously treated ovarian cancer patients, marking a significant expansion in cancer treatment options and likely increasing market share.
- Significant Clinical Trial Results: Data from the KEYNOTE-B96 trial showed that Keytruda combined with paclitaxel significantly improved progression-free survival (PFS) by reducing the risk of disease progression or death by 28%, providing new treatment options for patients.
- Improved Survival Rates: In PD-L1 positive patients, the median overall survival (OS) for the Keytruda treatment group was 18.2 months compared to 14.0 months for the placebo group, indicating a 24% reduction in the risk of death, further solidifying Keytruda's clinical value.
- Strong Sales Growth: Keytruda generated $8.37 billion in global sales in Q4 2025, representing a 7% year-over-year increase, driven by robust demand in earlier-stage indications, which is expected to enhance Merck's overall performance.
See More
Merck's KEYTRUDA Approved by FDA for Ovarian Cancer Treatment
- FDA Approval: Merck's KEYTRUDA® and KEYTRUDA QLEX™ have received FDA approval for the treatment of PD-L1+ platinum-resistant ovarian cancer, marking a significant advancement in treatment options and expected to improve patient survival rates.
- Clinical Trial Results: In the KEYNOTE-B96 trial, the KEYTRUDA plus paclitaxel treatment group demonstrated a 28% reduction in the risk of disease progression or death, with a median PFS of 8.3 months, significantly outperforming the placebo group's 7.2 months, indicating its clinical efficacy.
- Market Impact: This approval provides new treatment options for platinum-resistant ovarian cancer patients, expected to drive Merck's market share growth in the oncology immunotherapy sector, further solidifying its leadership in cancer treatment.
- Safety Warnings: The use of KEYTRUDA and KEYTRUDA QLEX is associated with severe immune-mediated adverse reactions, including pneumonia and renal impairment, prompting Merck to enhance patient monitoring and safety management to ensure treatment safety.
See More
FDA Approves Merck's Keytruda for Ovarian Cancer Treatment
- New Indication Approval: The US FDA has approved Merck's Keytruda (pembrolizumab) for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, marking a significant expansion of the drug's application in oncology.
- Combination Therapy: Keytruda will be administered in conjunction with paclitaxel and optionally with Avastin (bevacizumab), aiming to enhance patient survival rates and progression-free survival in these cancer types.
- Clinical Trial Support: The approval is based on the progression-free and overall survival results from the KEYNOTE-B96 trial, demonstrating Keytruda's efficacy in specific cancer patients and further solidifying its market position.
- Companion Diagnostic Tool: Additionally, the FDA approved Agilent Technologies' PD-L1 IHC 22C3 pharmDx companion diagnostic to identify patients who may benefit from Keytruda therapy, enhancing the precision and personalization of treatment options.
See More
Analyst Activity: Tesla and CrowdStrike Upgraded Amid Market Shifts
- Tesla Upgrade: Analyst Doron Levin upgraded Tesla (TSLA) from Hold to Buy, citing the company's $20 billion investment in robotaxi infrastructure as a speculative yet potentially rewarding bet on Musk's innovation, despite a history of missed deadlines and pivots.
- CrowdStrike Opportunity: Analyst Mike Zaccardi upgraded CrowdStrike (CRWD) from Hold to Buy, highlighting a 30% drawdown amid sector weakness as an attractive entry point, supported by robust fundamentals like 22% YoY revenue growth and record free cash flow.
- Stellantis Downgrade: Caffital Research downgraded Stellantis (STLA) from Buy to Hold, noting that while there are early signs of improvement in North America, the company's strategic reset and costly pullback on EV investments pose significant execution risks, leading to a 24% stock decline post-announcement.
- Merck Downgrade: The analyst downgraded Merck (MRK) from Buy to Hold, stating that after a 60% total return, the stock is now fairly valued, with the easy gains likely behind and significant risks from Keytruda erosion affecting future growth prospects.
See More
Analysis of VONE Stock Performance
- Price Range Analysis: VONE's stock has a 52-week low of $218.75 and a high of $316.38, with the last trade at $314.58, indicating that the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and optimal buying or selling opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify significant inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual stocks held within the ETFs.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
FDA Approves Merck's Keytruda for Ovarian Cancer Treatment
- FDA Approval for New Indication: The FDA approved Merck's Keytruda and Keytruda Qlex for previously treated ovarian cancer patients, marking a significant expansion in cancer treatment options and likely increasing market share.
- Significant Clinical Trial Results: Data from the KEYNOTE-B96 trial showed that Keytruda combined with paclitaxel significantly improved progression-free survival (PFS) by reducing the risk of disease progression or death by 28%, providing new treatment options for patients.
- Improved Survival Rates: In PD-L1 positive patients, the median overall survival (OS) for the Keytruda treatment group was 18.2 months compared to 14.0 months for the placebo group, indicating a 24% reduction in the risk of death, further solidifying Keytruda's clinical value.
- Strong Sales Growth: Keytruda generated $8.37 billion in global sales in Q4 2025, representing a 7% year-over-year increase, driven by robust demand in earlier-stage indications, which is expected to enhance Merck's overall performance.
See More
Merck's KEYTRUDA Approved by FDA for Ovarian Cancer Treatment
- FDA Approval: Merck's KEYTRUDA® and KEYTRUDA QLEX™ have received FDA approval for the treatment of PD-L1+ platinum-resistant ovarian cancer, marking a significant advancement in treatment options and expected to improve patient survival rates.
- Clinical Trial Results: In the KEYNOTE-B96 trial, the KEYTRUDA plus paclitaxel treatment group demonstrated a 28% reduction in the risk of disease progression or death, with a median PFS of 8.3 months, significantly outperforming the placebo group's 7.2 months, indicating its clinical efficacy.
- Market Impact: This approval provides new treatment options for platinum-resistant ovarian cancer patients, expected to drive Merck's market share growth in the oncology immunotherapy sector, further solidifying its leadership in cancer treatment.
- Safety Warnings: The use of KEYTRUDA and KEYTRUDA QLEX is associated with severe immune-mediated adverse reactions, including pneumonia and renal impairment, prompting Merck to enhance patient monitoring and safety management to ensure treatment safety.
See More
FDA Approves Merck's Keytruda for Ovarian Cancer Treatment
- New Indication Approval: The US FDA has approved Merck's Keytruda (pembrolizumab) for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, marking a significant expansion of the drug's application in oncology.
- Combination Therapy: Keytruda will be administered in conjunction with paclitaxel and optionally with Avastin (bevacizumab), aiming to enhance patient survival rates and progression-free survival in these cancer types.
- Clinical Trial Support: The approval is based on the progression-free and overall survival results from the KEYNOTE-B96 trial, demonstrating Keytruda's efficacy in specific cancer patients and further solidifying its market position.
- Companion Diagnostic Tool: Additionally, the FDA approved Agilent Technologies' PD-L1 IHC 22C3 pharmDx companion diagnostic to identify patients who may benefit from Keytruda therapy, enhancing the precision and personalization of treatment options.
See More
Analyst Activity: Tesla and CrowdStrike Upgraded Amid Market Shifts
- Tesla Upgrade: Analyst Doron Levin upgraded Tesla (TSLA) from Hold to Buy, citing the company's $20 billion investment in robotaxi infrastructure as a speculative yet potentially rewarding bet on Musk's innovation, despite a history of missed deadlines and pivots.
- CrowdStrike Opportunity: Analyst Mike Zaccardi upgraded CrowdStrike (CRWD) from Hold to Buy, highlighting a 30% drawdown amid sector weakness as an attractive entry point, supported by robust fundamentals like 22% YoY revenue growth and record free cash flow.
- Stellantis Downgrade: Caffital Research downgraded Stellantis (STLA) from Buy to Hold, noting that while there are early signs of improvement in North America, the company's strategic reset and costly pullback on EV investments pose significant execution risks, leading to a 24% stock decline post-announcement.
- Merck Downgrade: The analyst downgraded Merck (MRK) from Buy to Hold, stating that after a 60% total return, the stock is now fairly valued, with the easy gains likely behind and significant risks from Keytruda erosion affecting future growth prospects.
See More
